Ohio State Navbar

Our Team

Post-Doctoral Fellows

Dalia Elgamal PhD

Dr. ElGamal received her PhD in Experimental and Clinical Pharmacology from the Medical University of Graz in Austria where she studied the effects of cyanate-induced inflammation and its contribution to endothelial dysfunction. Dr. ElGamal joined the CLL experimental therapeutics lab in 2012 where she is examining the effects of a novel PKC inhibitor on primary CLL cells. She is also studying the involvement of PRMT5 in CLL transformation to Richter’s syndrome. This work will identify driver epigenetic events required for initiation and maintenance of the CLL and RS phenotype, wherein novel PRMT5 small molecule inhibitor(s) developed here at OSU will be explored in CLL.  

Bonnie Harrington DVM


Dr. Harrington is a veterinarian pursuing her PhD in Comparative and Veterinary Medicine and board certification in Veterinary Anatomic Pathology. Dr. Harrington received her DVM from The Ohio State University in 2012, and transitioned to the combined residency/PhD program immediately afterward. She joined the lab in 2013 under the co-mentorship of Drs. Amy Johnson and John Byrd. Her current project investigates novel therapeutics for treatment of CLL and mantle cell lymphoma.


Rajeswaran Mani DVM, PhD

Dr. Mani earned his PhD in Comparative and Veterinary Medicine from the Ohio State University in 2014. Before that Rajes received his BVSc & AH (DVM equivalent) from Madras Veterinary College in Chennai, India.  Using Comparative Medicine knowledge and skills, Dr. Mani is actively working on characterizing animal models of heme-malignancies for therapy evaluation. Dr. Mani is a member of the Targeted Therapies core under the direction of Dr. Raj Muthusamy.  

Aparna Lakshmanan PhD

Dr. Lakshmanan earned her PhD in Molecular, Cellular and Developmental Biology from The Ohio State University in May 2015 under the mentorship of Dr. Sissy M. Jhiang. During her graduate work, she identified a novel role for the plant-based flavonoid, Apigenin, in improving the efficacy of radioiodide therapy in thyroid cancer patients. She also discovered the first two microRNAs that modulate the iodide transporter, Na+/I- Symporter (NIS). With great interest in expanding her horizons to hematological malignancies and cancer-immune interplay, she joined the CLL experimental therapeutics lab in September 2015 for her postdoctoral training under the guidance of Drs. David Lucas and John Byrd. Her projects focus on mechanisms involved in immune modulation of cancer and novel therapeutics for CLL and AML with high potential for clinical impact.   

Fabienne McClanahan MD, PhD

Fabienne earned her medical degree and an intercalated medical doctorate degree in Cancer Epidemiology from Johannes Guttenberg University Mainz, Germany. She then received specialty Hematology/Oncology clinical and research training at the University Hospital and the German Cancer Research Center in Heidelberg. In early 2015, she obtained a Ph.D. in Cancer Immunology/ Hematology from the University of London, UK, under the mentorship of Prof. John Gribben. Her postdoctoral studies at OSU are conducted under the guidance of Dr. Woyach and focus on the crosstalk between immune components and leukemia cells in the context of novel targeted therapies.  A major component of this work is the  Pelotonia Postdoctoral Fellowship Program funded project “Correction of immune defects by ibrutinib in the setting of aging-related immune dysfunction in CLL”. Fabienne is also a recipient of the 2013 ASH/EHA Translational Research Training in Hematology (TRTH) mentorship award, and a Founding and Committee member of the Early Career Advisory Group of the European Hematology Association (EHA ECAG).  

Daphne Guinn PhD

Daphne joined the lab in the Autumn of 2011 for her graduate studies. She holds B.S. degrees in Toxicology and Biology from Ashland University. She earned her Ph.D. in Biomedical Science from The Ohio State University in May 2016. She is currently studying microRNA expression in CLL and ibrutinib resistance mechanisms. She is a member of the Molecular Pharmacology group under the direction of Dr. Amy Johnson and Dr. John Byrd.   

Sara Elgamal PhD

Sara earned her PhD in Microbiology from The Ohio State University in Autumn 2015 under the mentorship of Dr. Michael Ibba. She joined the lab in March 2016 for her postdoctoral training under the mentorships of Drs. Amy Johnson and John Byrd. Her work focuses on the role of exosomes in CLL pathogenesis.  

Clinical Fellows


Karilyn Larkin MD


Nicole Grieselhuber MD, PhD


Meixiao Long MD, PhD


Dr. Long received his Ph.D in Biomedical Sciences from University of Connecticut under the direction of Adam Adler PhD where he studied immune tolerance of T cells.  Afterwards he worked in Dr. Sankar Ghosh’s lab at Yale University and later Columbia University studying the regulation of NF-kB pathway in the immune system and regulatory T cell development.  In 2013, he came to The Ohio State University as a fellow in Hematology and Oncology. He joined the CLL experimental therapeutics lab in 2014 where his current projects are focusing on studying leukemia/lymphoma induced immune suppression and immunotherapy.